Vemurafenib-induced pityriasis amiantacea: a case report
Küçük Resim Yok
Tarih
2016
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
TAYLOR & FRANCIS LTD
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Vemurafenib, a novel treatment for patients with BRAF-positive metastatic melanoma, is associated with a wide spectrum of cutaneous adverse events both benign and malignant. Vemurafenib-induced pityriasis amiantacea (PA), a scaling reaction of the scalp that may cause temporary or cicatricial alopecia, has not yet been reported in the literature. In the present case, PA was observed two months after the initiation of vemurafenib therapy for metastatic melanoma and managed with symptomatic treatment without the need to cease or modify the vemurafenib dosage.
Açıklama
Anahtar Kelimeler
BRAF inhibitor, cutaneous side effects, dermatitis, eruptive milia, melanoma, photosensitivity, seborrheic dermatitis like eruption, tinea amiantacea
Kaynak
CUTANEOUS AND OCULAR TOXICOLOGY
WoS Q Değeri
Q4
Scopus Q Değeri
Q3
Cilt
35
Sayı
4
